Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Colorcon
McKesson
Baxter
Medtronic

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Doxazosin mesylate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for doxazosin mesylate and what is the scope of freedom to operate?

Doxazosin mesylate is the generic ingredient in three branded drugs marketed by Pfizer, Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Upsher Smith Labs, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for doxazosin mesylate. Thirty-one suppliers are listed for this compound.

Drug Prices for doxazosin mesylate

See drug prices for doxazosin mesylate

Drug Sales Revenue Trends for doxazosin mesylate

See drug sales revenues for doxazosin mesylate

Recent Clinical Trials for doxazosin mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerN/A
University of Minnesota - Clinical and Translational Science InstitutePhase 2
National Heart, Lung, and Blood Institute (NHLBI)Phase 2

See all doxazosin mesylate clinical trials

Pharmacology for doxazosin mesylate
Medical Subject Heading (MeSH) Categories for doxazosin mesylate
Synonyms for doxazosin mesylate
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone methanesulfonate
[1,4]dioxin-2-yl)methanone methanesulfonate
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-2-yl)methanone; methanesulfonic acid
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone;methanesulfonic acid
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanonemethanesulfonic acid
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL) PIPERAZINE METHANESULFONATE
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine monomethanesulfonate
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzoldioxan-2-ylcarbonyl)piperazine methanesulfonate
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(1,4-benzodioxan-2-yl)carbonyl]piperazine Methanesulfonate
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine mesylate
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid
4-Amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline methanesulfonate
74191-85-8 (Parent)
77883-43-3
91D858
AB0008587
AB2000045
AC-6848
AC1L1Y5G
AC1Q4GSV
AC1Q4GT3
AKOS015895371
Alfadil
AN-9627
ANW-42738
BCP12163
Benur
C23H25N5O5.CH4O3S
C24H29N5O8S
Cardenalin
Cardoral
Cardoxan
Cardular
Cardular PP
Cardular Uro
Cardura
Cardura (TN)
Cardura XL
Cardura;Carduran;Cardura XL
Carduran
Carduran Neo
CAS-77883-43-3
CCG-213583
CHEBI:4709
CHEMBL1200561
CPD000058441
CS-1830
CTK7B4527
D 9815
D00608
D4126
Dedralen
Diblocin
Diblocin PP
Diblocin Uro
Doksura
Dosin
Doxaben
Doxazocine
Doxazomerck
Doxazosin (mesylate)
Doxazosin AZU
Doxazosin mesilate
Doxazosin mesilate (JP17)
Doxazosin mesilate, European Pharmacopoeia (EP) Reference Standard
Doxazosin mesylate (USAN)
Doxazosin mesylate [USAN:USP]
Doxazosin mesylate [USAN]
doxazosin mesylate salt
Doxazosin mesylate, >=97% (HPLC), powder
Doxazosin mesylate, United States Pharmacopeia (USP) Reference Standard
Doxazosin Mesylate,(S)
Doxazosinmesylate
Doxolbran
DSSTox_CID_25598
DSSTox_GSID_45598
DSSTox_RID_80991
DTXSID5045598
Duracin
EN300-53021
EU-0100474
FT-0625592
HMS1570L17
HMS2093J14
HMS2097L17
HMS2230L18
HMS3261O10
HMS3372C03
HMS3654J15
HMS3714L17
HSDB 7082
HY-B0098A
I06-0611
J10294
Kaltensif
KS-1052
LP00474
LS-110229
MFCD00216023
MLS000028455
MLS000120399
MLS001148153
MLS002222292
MLS006011977
MolPort-003-983-427
NCGC00016146-02
NCGC00017136-01
NCGC00018158-09
NCGC00093884-01
NCGC00261159-01
NE52844
Normathen
NSC-759284
NSC759284
Opera_ID_1881
Pharmakon1600-01505976
piperazin-1-yl)(2,3-dihydrobenzo[b]
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, monomethanesulfonate
Prestwick_1026
Progandol
Prostadilat
PubChem2385
RW2756
s1324
SAM002589903
SCHEMBL42621
SMR000058441
SR-01000003045
SR-01000003045-2
SR-01000003045-4
SR-01000003045-8
Supressin
SW197099-3
Tensiobas
TL8005338
Tonocardin
Tox21_110796
Tox21_110796_1
Tox21_500474
UK 33,274-27
UK-33,274-27
UK-33274
UK-33274-27
UK-3327427
VJECBOKJABCYMF-UHFFFAOYSA-N
Z1259084903
Paragraph IV (Patent) Challenges for DOXAZOSIN MESYLATE
Tradename Dosage Ingredient NDA Submissiondate
CARDURA TABLET;ORAL doxazosin mesylate 019668

US Patents and Regulatory Information for doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 202824-003 Jun 11, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Nesher Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075609-004 Oct 18, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Pliva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075750-004 Jun 8, 2001 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-002 Feb 22, 2005   Start Trial   Start Trial
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-003 Nov 2, 1990   Start Trial   Start Trial
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Harvard Business School
Medtronic
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.